Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

Shots:

• The P-III studies include REGAIN and EVOLVE-1 & 2 assessing Emgality vs PBO in patients with chronic and episodic migraine respectively
• Post-hoc analyses results: reductions in disability in chronic migraine (20.3% vs 13.9%); @6mos. little/no disability in episodic migraine (44.0% vs 26.5%); improvement in daily functioning
• Emgality is a mAb targeting CGRP and has received EMA’s approval for the prophylaxis of migraine in Nov’2018 and FDA’s approval for migraine and episodic cluster headache in adults in Sept’2018 and Jun’2019 respectively

Click here to read full press release/ article | Ref: Lilly | Image: Behance